Back to Journals » Oncolytic Virotherapy » Volume 7

Oncolytic virus and PD-1/PD-L1 blockade combination therapy

Authors Chen CY, Hutzen B, Wedekind MF, Cripe TP

Received 22 February 2018

Accepted for publication 1 May 2018

Published 31 July 2018 Volume 2018:7 Pages 65—77


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Chun-Yu Chen,1 Brian Hutzen,1 Mary F Wedekind,1,2 Timothy P Cripe1,2

1Department of Pediatrics, Center for Childhood Cancer and Blood Diseases, Nationwide Children’s Hospital, 2Division of Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH, USA

Abstract: Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy.

Keywords: cancer, viral oncolysis, immunotherapy, immune checkpoint blockade

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]